A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model

Arthropod-borne and Infectious Diseases Laboratory, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, 80523, USA.
Antiviral research (Impact Factor: 3.94). 02/2012; 94(1):1-8. DOI: 10.1016/j.antiviral.2012.02.001
Source: PubMed


Yellow fever virus (YFV), a member of the genus Flavivirus, is a mosquito-borne virus found in tropical regions of Africa and South America that causes severe hepatic disease and death in humans. Despite the availability of effective vaccines, YFV is responsible for an estimated 200,000 cases and 30,000 deaths annually. There are currently no prophylactic or therapeutic strategies approved for use in human YFV infections. Furthermore, implementation of YFV 17D-204 vaccination campaigns has become problematic due to an increase in reported post-vaccinal adverse events. We have created human/murine chimeric MAbs of a YFV-reactive murine monoclonal antibody (mMAb), 2C9, that was previously shown to protect mice from lethal YFV infection and to have therapeutic activity. The new chimeric (cMAbs) were constructed by fusion of the m2C9 IgG gene variable regions with the constant regions of human IgG and IgM and expressed in Sp2 murine myelomas. The 2C9 cMAbs (2C9-cIgG and 2C9-cIgM) reacted with 17D-204 vaccine strain in an enzyme-linked immunosorbent assay and neutralized virus in vitro similarly to the parent m2C9. Both m2C9 and 2C9-cIgG when administered prophylactically 24h prior to infection protected AG129 mice from peripheral 17D-204 challenge at antibody concentrations ≥1.27 μg/mouse; however, the 2C9-cIgM did not protect even at a dose of 127 μg/mouse. The 17D-204 infection of AG129 mice is otherwise uniformly lethal. While the m2C9 was shown previously to be therapeutically effective in YFV-infected BALB/c mice at day 4 post-infection, the m2C9 and 2C9-cIgG demonstrated therapeutic activity only when administered 1 day post-infection in 17D-204-infected AG129 mice.

Download full-text


Available from: Joseph Piper
  • Source
    • "In contrast, YFV-17D-immune subjects were fully protected against YFV-17D that express the homologous envelope proteins (38, 40). The protection in this case may be largely due to neutralizing antibodies since prior studies have demonstrated that adoptive transfer of immune serum alone provides partial to full protective immunity against lethal YFV in rhesus macaques (RM) (41), hamsters (42), and immunodeficient mice (43). "
    [Show abstract] [Hide abstract]
    ABSTRACT: It is estimated that over 2.5 billion people are at risk for contracting dengue, a virus responsible for 50-390 million infections in addition to thousands of hospitalizations and deaths each year. There are no licensed vaccines available to combat this pathogen but substantial efforts are underway to develop live-attenuated, inactivated, and subunit vaccines that will protect against each of the four serotypes of dengue. Unfortunately, the results of a recent Phase IIb efficacy trial involving a tetravalent live-attenuated chimeric dengue virus vaccine have raised questions with regard to our current understanding of vaccine-mediated immunity to this important flavivirus. Here, we will briefly summarize these vaccination efforts and discuss the importance of informative in vivo models for determining vaccine efficacy and the need to establish a quantitative correlate of immunity in order to predict the duration of vaccine-induced antiviral protection.
    Full-text · Article · May 2014 · Frontiers in Immunology
    • "Antibody Humanization method Disease/application Type Reference Anti-TAG-72 Human VL + humanized VH genes Human adenocarcinomas of the pancreas scAb Pavlinkova et al., 2001) Hu 9.3(anti CD-28) CDR homology + germline humanization GVHD, autoimmune disease, transplantation Fab Tan et al., 2002 humanized H23 anti- MUC1 CDR grafting Breast cancer scAb Mazor et al., 2005 AKA SDR grafting Anti-tumor-associated glycoprotein-72 Full length Yoon et al., 2006 h82D6A3 Variable domain resurfacing Inhibiting VWFinteraction to fibrillar collagen Full length Staelens et al., 2006 KD-247 Sequential immunization with V3 peptides HIV-1 Full length Eda et al., 2006 HzKR127 Phage display technique Hepatitis B scAb + full length Yang et al., 2007 Anti-lysozyme antibody D1.3. CDR homology-based humanization – Full length Hwang et al., 2005 35PA83 FR homology germline humanization Anthrax Fab Pelat et al., 2008 Humanized anti-RAGE FR homology germline humanization Multi inflammatory diseases scFv Finlay et al., 2009 Anti CD19 antibody FR homology germline humanization + point mutations Human B-cell malignancies scAb Kugler et al., 2009 Anti- CEACAM6 CDR grafting + conversion of some residues in FWRs Pancrease cancer scAb Riley et al., 2009 Humanized EBV321 Mutational lineage guided MLG Lung carcinoma Full length Yu et al., 2010 hWO-2 Germline humanization with retaining the vernier zone Alzheimers scAb Robert et al., 2010 h357 Resurfacing of both VH and VL domain TNF-α antibody Full length Chiu et al., 2011 Anti-HCV Phage display Hepatitis C scAb Lun et al., 2011 Anti-human integrin αvβ3 Phage antibody display Anti-angiogenesis therapy scFv Liu et al., 2011 2C9 Fusion of m2c9 variable regions to human constant regions Yellow fever Full length + chimeric Thibodeaux et al., 2012 Anti-GD2 CDR grafting on human IgG1 and IgG4 frameworks Neuroblastoma Full length Cheung et al., 2012 hDB32-6 CDR grafting on human IgG1 + mutation in all FRs Dengue virus infection Full length Li et al., 2012 "
    [Show abstract] [Hide abstract]
    ABSTRACT: This article reviews recent advances achieved during recent years on various aspects of antibody humanization theories and techniques. Common methods for producing humanized antibodies including framework-homology-based humanization, germline humanization, complementary determining regions (CDR)-homology-based humanization and specificity determining residues (SDR) grafting, as well as advantages and disadvantages of each of these methods and their applications are discussed.
    No preview · Article · Oct 2013 · Biotechnology & genetic engineering reviews
  • Source
    • "Appreciable results were also obtained when both murine 2C9 and 2C9-cIgG were administered 24 hours post-infection, with the survival of 70% and 20% of mice, respectively. Viral presence was not detected in surviving mice [60]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: More than 150 arboviruses belonging to different families are known to infect humans, causing endemic infections as well as epidemic outbreaks. Effective vaccines to limit the occurrence of some of these infections have been licensed, while for the others several new immunogens are under development mostly for their improvements concerning safety and effectiveness profiles. On the other hand, specific and effective antiviral drugs are not yet available, posing an urgent medical need in particular for emergency cases. Neutralizing monoclonal antibodies (mAbs) have been demonstrated to be effective in the treatment of several infectious diseases as well as in preliminary in vitro and in vivo models of arbovirus-related infections. Given their specific antiviral activity as well-tolerated molecules with limited side effects, mAbs could represent a new therapeutic approach for the development of an effective treatment, as well as useful tools in the study of the host-virus interplay and in the development of more effective immunogens. However, before their use as candidate therapeutics, possible hurdles (e.g., Ab-dependent enhancement of infection, occurrence of viral escape variants) must be carefully evaluated. In this review are described the main arboviruses infecting humans and candidate mAbs to be possibly used in a future passive immunotherapy.
    Full-text · Article · Aug 2013
Show more